Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Keros Therapeutics ( (KROS) ) has shared an announcement.
On February 24, 2026, Keros Therapeutics’ board appointed former Lyell Immunopharma CFO and veteran healthcare investment banker Charles Newton as a Class III director, effective March 9, 2026, with a term running through the 2026 annual meeting. He will also join the Compensation and Audit Committees and receive the company’s standard mix of equity awards and cash retainers for non-employee directors, along with a standard indemnification agreement.
The appointment, announced publicly on February 26, 2026, brings deep healthcare finance and capital markets experience onto Keros’ board as it advances its clinical pipeline, including rinvatercept. Concurrently, longtime director Carl Gordon will step down from the board and the Compensation Committee on March 9, 2026, a move the company said was not due to any disagreement and that prompted a refresh of committee memberships across its three standing board committees.
The most recent analyst rating on (KROS) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
The score is driven primarily by improving financial performance and a strong, low-leverage balance sheet, supported by reasonable valuation and positive corporate actions (capital return and strategy updates). These positives are tempered by weaker near-term technical momentum (negative MACD, RSI below 50, and price below the 20-day average).
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing and commercializing novel protein therapeutics targeting disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Its pipeline includes lead product candidate rinvatercept for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and elritercept for cytopenias such as anemia and thrombocytopenia in myelodysplastic syndrome and myelofibrosis patients.
Average Trading Volume: 479,887
Technical Sentiment Signal: Strong Sell
Current Market Cap: $472.8M
See more data about KROS stock on TipRanks’ Stock Analysis page.